Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by lonc17on May 11, 2023 6:23pm
432 Views
Post# 35444287

Bracelet OS

Bracelet OSMarch Corporate Presentation on ONC's Website, page 28:

BRACELET-1 mBC study: ORR, PFS, evolving OS data Q2 2023

And now we here from MC telling us not to expect any OS data at ASCO. And it seems likely no OS data till early 2024!

What changed between March and May?

How can they promise evolving OS data by June, and then push it out at least six months?

Sadly, I believe I know the reason. If the evolving OS data was definitively positive, they would release it. If not, then wait till it "matures" further. 

Another clue on the quarterly call was the helpful suggestion that we should not expect any BD deal or news quickly after ASCO. 

WHY THE H*LL NOT?

Serioulsy, all interested parties have had months to examine the data thoroughly. If it was as astounding as we are hoping, then a deal would materialize soon enough. 

The market does not appear to be impressed with the "oral" presentation. Given recent comments from ONC, I'm not at all surprised. 
<< Previous
Bullboard Posts
Next >>